• Explore /
  • Poster
  • / A UK real-world observational study of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): Outcomes at 36 months post treatment initiation.

A UK real-world observational study of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): Outcomes at 36 months post treatment initiation.

Abstract Poster

Authors

null

Paul D. Nathan

Mount Vernon Cancer Center, Northwood, United Kingdom

Paul D. Nathan , Natalie Charnley , Ricky Frazer , John McGrane , Iqtedar Muazzam , Manon Pillai , Sarah Rudman , Anand Sharma , Robert Stevenson , Balaji Venugopal , Joseph David Hickey , Aimi Rose Ritchie , Kin Liu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer

Sub Track

Quality of Care/Quality Improvement and Real-World Evidence

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 386)

DOI

10.1200/JCO.2024.42.4_suppl.386

Abstract #

386

Poster Bd #

F10

Abstract Disclosures

Similar Posters

First Author: Paul D. Nathan

First Author: Paul D. Nathan

First Author: Viktor Grünwald

First Author: Sonam Ansel